Betta Pharmaceuticals (China) Performance
| 300558 Stock | 52.69 1.11 2.06% |
On a scale of 0 to 100, Betta Pharmaceuticals holds a performance score of 14. The firm shows a Beta (market volatility) of -0.0281, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Betta Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Betta Pharmaceuticals is likely to outperform the market. Please check Betta Pharmaceuticals' total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Betta Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Betta Pharmaceuticals Co are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Betta Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0032 | Payout Ratio 0.1753 | Forward Dividend Rate 0.17 | Ex Dividend Date 2024-06-06 |
1 | Betta Pharmaceuticals Co., Ltd.s PE Is Still On The Mark Following 29 percent Share Price Bounce - Simply Wall St | 09/30/2024 |
2 | Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - StockTitan | 10/31/2024 |
| Begin Period Cash Flow | 731.3 M |
Betta |
Betta Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 3,550 in Betta Pharmaceuticals Co on August 30, 2024 and sell it today you would earn a total of 1,830 from holding Betta Pharmaceuticals Co or generate 51.55% return on investment over 90 days. Betta Pharmaceuticals Co is generating 0.8214% of daily returns and assumes 4.6161% volatility on return distribution over the 90 days horizon. Simply put, 41% of stocks are less volatile than Betta, and 84% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Betta Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Betta Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Betta Pharmaceuticals Co, and traders can use it to determine the average amount a Betta Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.178
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 300558 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.62 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.82 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Betta Pharmaceuticals is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Betta Pharmaceuticals by adding it to a well-diversified portfolio.
Betta Pharmaceuticals Fundamentals Growth
Betta Stock prices reflect investors' perceptions of the future prospects and financial health of Betta Pharmaceuticals, and Betta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Betta Stock performance.
| Return On Equity | 0.0804 | ||||
| Return On Asset | 0.028 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 24.03 B | ||||
| Shares Outstanding | 418.49 M | ||||
| Price To Book | 3.99 X | ||||
| Price To Sales | 8.33 X | ||||
| Revenue | 2.46 B | ||||
| Gross Profit | 2.07 B | ||||
| EBITDA | 743.57 M | ||||
| Net Income | 348.03 M | ||||
| Total Debt | 300.27 M | ||||
| Book Value Per Share | 13.47 X | ||||
| Cash Flow From Operations | 914.23 M | ||||
| Earnings Per Share | 1.09 X | ||||
| Total Asset | 9.15 B | ||||
| Retained Earnings | 2.29 B | ||||
About Betta Pharmaceuticals Performance
By analyzing Betta Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Betta Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Betta Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Betta Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Betta Pharmaceuticals is entity of China. It is traded as Stock on SHE exchange.Things to note about Betta Pharmaceuticals performance evaluation
Checking the ongoing alerts about Betta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Betta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Betta Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| About 48.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - StockTitan |
- Analyzing Betta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Betta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Betta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Betta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Betta Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Betta Pharmaceuticals' stock. These opinions can provide insight into Betta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Betta Stock analysis
When running Betta Pharmaceuticals' price analysis, check to measure Betta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Betta Pharmaceuticals is operating at the current time. Most of Betta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Betta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Betta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Betta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |